Кортинефф

Quick links to important sections

Кортинефф

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Кортинефф

Quick Facts

Property Description
Active ingredient Fludrocortisone acetate
Form Oral tablet
Pharmacological class Mineralocorticoid / Synthetic Corticosteroid
Common use Hormone replacement therapy for deficiency states
Origin Synthetic (derived from cortisol)

Кортинефф is a specific pharmaceutical preparation of Fludrocortisone acetate available as an oral tablet, clinically recognized for its essential role in hormone replacement therapy when the body's natural production of steroid hormones is insufficient. Its core purpose is to substitute the effects of these hormones, mainly to maintain critical fluid and electrolyte stability within the body.


What Type of Medicine is Кортинефф? (Identity and Class)

Кортинефф is classified as a potent synthetic corticosteroid, primarily belonging to the pharmacological group of mineralocorticoids. The active ingredient, Fludrocortisone acetate (INN), is designed to exert powerful mineralocorticoid effects, governing the retention of salt and water. This compound is characterized by high systemic activity in electrolyte balance. Unlike general corticosteroids, its action profile is unique, marked by a dominant influence on electrolyte management compared to its lesser, but present, glucocorticoid activity.


Composition, Origin, and Pharmaceutical Form (Structure and Source)

The medication is composed of the active substance Fludrocortisone acetate along with necessary solid excipients required to form an oral tablet for systemic administration. Fludrocortisone is a synthetic compound, specifically a halogenated derivative of the natural hormone cortisol, chemically modified to enhance its potency in regulating fluid balance. This structural modification is associated with a significantly heightened effectiveness for salt-retaining effects. The tablet form provides a reliable method for sustained daily dosing, which is necessary for consistent, long-term replacement therapy.


General Purpose: Restoring Hormone and Electrolyte Balance (High-Level Function)

The general function of Кортинефф is to restore crucial internal balance. Fludrocortisone acts in the kidneys to enhance the reabsorption of sodium (salt) and water, which is fundamental for maintaining adequate circulating fluid volume and healthy plasma electrolyte composition. By performing this vital role, the medicine helps support stable blood pressure and prevents the critical fluid loss associated with states of adrenal or hormonal deficiency.

Regulatory References

  1. Fludrocortisone Acetate Drug Information
  2. FDA Label for Fludrocortisone Acetate
  3. Fludrocortisone Acetate DailyMed Label

What side effects are possible with Кортинефф?

Possible side effects and safety information

The safety profile of Fludrocortisone acetate is officially documented by health authorities, focusing on adverse reactions related to its mineralocorticoid activity and general systemic corticosteroid effects. Safety classifications are typically grouped by frequency and System-Organ Class (SOC).


Officially Classified Adverse Reactions

The most frequently documented effects are related to the medicine's influence on fluid and electrolyte balance.

Classification Examples of Documented Effects (SOC)
Very Common Hypokalaemia (low blood potassium), Hypertension (high blood pressure), Congestive cardiac failure (Vascular/Cardiac/Metabolism)
Common Oedema (fluid retention), Muscular weakness, Headache (General/Musculoskeletal/Nervous System)
Uncommon Seizure, Syncope, Hallucination, Diarrhoea (Nervous System/Psychiatric/Gastrointestinal)

Serious Adverse Reactions and Safety Patterns

Official prescribing information lists serious adverse reactions associated with systemic corticosteroid use across several organ systems, independent of frequency classification. These include peptic ulcer with possible perforation, osteoporosis, vertebral fractures, glaucoma, posterior subcapsular cataracts, and increased intracranial pressure (Pseudotumor cerebri).

Time- and Population-Related Safety Notes

Certain risks are explicitly tied to duration of exposure. Prolonged use is associated with an increased risk of developing cataracts, glaucoma, and bone density loss. Furthermore, the label defines specific safety considerations for patient groups. For example, older adults may be more susceptible to the serious consequences of common effects, and growth suppression has been reported in the pediatric population.

High-Level Restrictions

The medicine is formally contraindicated for use in patients with known systemic fungal infections or a documented history of hypersensitivity to the agent, as stated in regulatory documents.

Overdose and Emergency Response

Overdose Manifestations and Complications

Overdosage of Fludrocortisone acetate typically results from an exaggeration of its potent mineralocorticoid activity. This is primarily characterized by severe fluid and electrolyte disturbances. Documented manifestations include marked hypertension (high blood pressure), generalized edema (fluid retention), and significant hypokalemia (low serum potassium levels), often causing muscular weakness. Prolonged high exposure may result in the development of a Cushingoid state.

The regulatory profile highlights that excessive mineralocorticoid activity can lead to serious outcomes, particularly in susceptible individuals. These severe manifestations include the onset or exacerbation of congestive heart failure. Furthermore, acute events such as seizure or collapse are listed as critical complications.

When to Seek Urgent Medical Help

Immediate medical attention is required for any suspected overdose. Government regulatory authorities mandate specific actions for severe presentations. Emergency services must be called immediately if the affected individual has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. In all cases of suspected overdose, contacting the Poison Control helpline is also a specified action.

Management procedures involve discontinuing the medication and initiating careful monitoring of serum electrolytes, specifically sodium and potassium levels. Treatment focuses on supportive measures to correct any physiological imbalances, as no specific antidote is documented in the official prescribing information.

Therapeutic Uses of Кортинефф

What Кортинефф Treats: Main Uses and Benefits

Кортинефф (Fludrocortisone) is applied across domains where additional symptomatic support is needed to address symptoms related to certain distressing symptoms stemming from adrenal hormone deficiency. It is commonly used to help with conditions characterized by periods of heightened symptoms, such as Addison's disease and specific salt-losing syndromes. Its purpose is to support symptomatic management and is considered relevant for easing symptoms that create noticeable physiological strain.


Key Areas of Symptom Management

This medication is considered relevant for individuals with conditions like adrenal insufficiency. It helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability by managing symptoms related to systemic imbalance, including frequent dizziness and light-headedness, and is applied in contexts where additional symptomatic support is needed for symptoms related to systemic imbalance.

“It is commonly used to help with symptoms that create noticeable physiological strain and supports general well-being during symptomatic phases.”

Quick Fact: Support for Low Blood Pressure Symptoms

Кортинефф provides supportive relief when symptoms interfere with routine activities, is used for managing symptoms of persistent low blood pressure associated with chronic weakness, and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Кортинефф — official regulatory information

Eligibility scope Regulatory Statement (Strictly Label-Based)
Populations for whom use is allowed Patients receiving partial replacement therapy for primary adrenocortical insufficiency (Addison's disease) and for the treatment of salt-losing adrenogenital syndrome.
Populations for whom use is contraindicated Patients with documented systemic fungal infections or a known hypersensitivity to the formulation. Co-administration with live vaccines is also prohibited for patients receiving immunosuppressive doses.
Age-related eligibility rules Pediatric Patients: Safety and effectiveness have not been established in children. Growth and development require careful monitoring during prolonged therapy. Older Adults: Use requires caution due to the greater frequency of decreased organ function (renal, hepatic, cardiac).
Condition-specific eligibility rules Use requires caution in patients with: renal insufficiency, hypertension, cirrhosis (hepatic impairment), hypothyroidism, diabetes mellitus, and active or latent peptic ulcer.
Pregnancy and lactation eligibility status Pregnancy: Classified as FDA Category C. Use is contingent upon weighing potential benefits against hazards. Lactation: Corticosteroids are secreted into human milk; caution is advised.

Eligibility classifications (high-level) Regulatory Statement (Strictly Label-Based)
Eligibility severity classification Contraindicated (Systemic fungal infections); Category C (Pregnancy); Use Not Established (Pediatrics).

Official eligibility statements:

  • The medicine is contraindicated in patients with a systemic fungal infection or a known hypersensitivity to the drug substance.
  • Eligibility is restricted for pediatric patients, as the safety and effectiveness have not been established in children.
  • Use is conditioned by the presence of comorbidities such as renal insufficiency, cirrhosis, or hypertension, where the label mandates caution.

Connection to the overall eligibility profile: Governmental regulatory documents strictly define who can and cannot use Кортинефф by establishing absolute contraindications based on infection and hypersensitivity, and by imposing numerous conditional limitations tied to organ function and existing chronic diseases. This regulatory structure differentiates between approved use in adults for specific hormone deficiency states and non-established use in pediatric populations, providing a clear, non-advisory framework for patient eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Кортинефф (Fludrocortisone acetate) documents several categories of interactions, primarily influencing metabolism or electrolyte balance. All interaction statements reflect restrictions or monitoring requirements as defined in official prescribing information.

Pharmacodynamic and Metabolic Interactions

Interacting Agent Category Official Interaction Outcome
Potassium-Depleting Agents (e.g., specific diuretics, Amphotericin B) Enhanced hypokalemia (excessive potassium loss) is documented, requiring frequent monitoring of serum potassium levels and posing an increased risk of digitalis toxicity with co-administered glycosides.
Hepatic Enzyme Inducers (e.g., Phenytoin, Rifampin, Barbiturates) Causes increased metabolic clearance of Fludrocortisone due to enzyme induction, which may result in a diminished therapeutic steroid effect.
Antidiabetic Drugs (e.g., Insulin, oral agents) The therapeutic effect is diminished due to the steroid's influence on blood glucose, requiring monitoring for hyperglycemia.
Anticoagulants (e.g., Warfarin) The anticoagulant action may be altered, necessitating close monitoring of prothrombin levels and potential dosage adjustment.

Specific Restrictions and Substance Interactions

Fludrocortisone is formally contraindicated for use in the presence of systemic fungal infections unless specific anti-infective therapy is concurrently employed. Furthermore, live or live attenuated vaccines should generally not be administered during treatment. The regulatory documents note that co-administration with anabolic steroids may increase the tendency toward edema, a consideration that is heightened in patients with pre-existing cardiac or hepatic disease. The official labeling also notes potential interactions with Alcohol and Licorice.

Mechanism of Action

Кортинефф, which is fludrocortisone acetate, functions as a synthetic mineralocorticoid with a high affinity for the mineralocorticoid receptor (MR). Its primary target is the MR, a ligand-activated intracellular transcription factor predominantly expressed in the epithelial cells of the distal renal tubules and collecting ducts, as well as in other tissues like the colon and heart.

Upon binding, fludrocortisone acetate initiates the conformational change and nuclear translocation of the MR-ligand complex. In the nucleus, this complex interacts with Glucocorticoid Response Elements (GREs) or Mineralocorticoid Response Elements (MREs) in the promoter region of target genes. This transcriptional modulation upregulates the synthesis of proteins crucial for ion transport, including the Epithelial Sodium Channel (ENaC) and the Na^+/ K^+-ATPase.

The resulting increase in ENaC activity in the apical membrane of principal cells enhances sodium reabsorption from the tubular lumen. This passive Na^+ movement drives the secondary secretion of potassium^+ and hydrogen^+ ions into the lumen. The augmented renal sodium reabsorption facilitates the osmotic retention of water, leading to an expansion of extracellular fluid volume and modulation of systemic blood pressure.

Dosage and Administration Information

How to Use Cortineff (Fludrocortisone Acetate) — Administration Guidelines

Cortineff (fludrocortisone acetate) is a mineralocorticoid replacement medicine that is used according to prescribing instructions. The following details the procedural steps for administration.


Official Administration Protocol

Administration Scope Detail
Route of Administration The drug is for oral administration as a tablet that is swallowed whole.
Dosing Schedule Dosing is individualized. The usual maintenance dose for adults with adrenocortical insufficiency is 0.1 mg daily, though the range can be from 0.1 mg three times a week up to 0.2 mg daily. The lowest effective dose is utilized.
Frequency Pattern Typically administered once daily, although divided doses may be used in certain pediatric regimens.

Special Procedural Conditions

Combination Requirement: Fludrocortisone is administered in conjunction with a glucocorticoid (e.g., hydrocortisone or cortisone). It is not intended for use as a sole treatment.

Dose Adjustment for Stress: The dosage is increased during periods of significant physical stress (e.g., severe illness, fever, trauma, or surgery) to prevent acute adrenal crisis. Conversely, the dose is reduced if signs of transient hypertension or edema develop.

Cessation of Use: Fludrocortisone is not stopped abruptly. When discontinuing the medication, the dosage is gradually reduced under the direction of a healthcare provider to avoid inducing secondary adrenocortical insufficiency.

Recent Clinical Evidence

Research evidence / Overview of studies for Кортинефф

The following overview summarizes the types of official research that have been conducted on Fludrocortisone acetate (Кортинефф), the outcomes that were measured, and the limitations or gaps that exist in the evidence, according to regulatory and peer-reviewed sources.


Evidence for Hormone Replacement in Adrenal Deficiency

For conditions like Primary Adrenal Insufficiency (Addison's disease), the evidence consists of long-term observational cohort studies and registry data. Researchers primarily monitored outcomes related to systemic imbalance, such as the stability of plasma electrolyte composition and Plasma Renin Activity (PRA). Findings describe patterns observed in these studies, documenting the essential role for mineralocorticoid replacement. Research gaps exist regarding optimal management goals for biomarkers like PRA. Evidence involving children with congenital adrenal hyperplasia is also available in this setting.


Evidence for Managing Symptoms of Low Blood Pressure

Fludrocortisone was evaluated in research exploring temporary physiological imbalance, such as Orthostatic Hypotension (OH). Studies consisted of small, short-term Randomized Controlled Trials (RCTs) that examined changes in postural blood pressure and patient-reported outcomes describing perceived discomfort. Findings regarding blood pressure measurements varied across different short-term studies, and certainty remains low due to the modest sample sizes and limited follow-up durations. Subgroups of older adults were included in some of these trials.


Evidence in Acute Salt-Wasting Clinical Situations

This medicine was evaluated in research involving patients with acute, specific salt-losing syndromes, such as Cerebral Salt Wasting (CSW) following neurological injuries. Small-scale RCTs monitored outcomes like the time to correction of low serum sodium levels. Findings describe patterns observed in the studies suggesting that the medicine may be associated with faster normalization of sodium levels. However, the systematic review findings indicate that evidence is limited by the size and design of the included trials.


What Remains Uncertain in the Research Landscape

While High level long-term observational data supports its essential role in hormone replacement, evidence quality varies across studies for the supportive uses. The main uncertainties stem from the trials for symptomatic low blood pressure, where comparative evidence is lacking against other non-medicinal management strategies, and long-term effects are not fully established.

Key Studies & References

  1. Fludrocortisone Acetate: MedlinePlus Drug Information
  2. Hyponatremia in the neurocritical care patient: An approach based on current evidence (Review on Salt Wasting)

Frequently Asked Questions (FAQ)

Common questions about Кортинефф (FAQ)

Q: How does Кортинефф differ in its effects compared to more common steroids like prednisone?

According to official product information, Кортинефф is prescribed mainly for its potent mineralocorticoid effects. This means its primary function is to manage the body's salt and water balance. Other commonly known steroids, like prednisone, are primarily used for their glucocorticoid properties, which focus more on reducing inflammation.

Q: Does taking Кортинефф commonly lead to changes in mood or anxiety levels?

Official regulatory documents note that corticosteroids can cause psychiatric disturbances. These possible effects include changes in temperament such as mood swings, increased anxiety, nervousness, or confusion. Official documents recommend reporting changes in mood to a healthcare provider.

Q: Is weight gain a common or expected side effect of using Кортинефф?

Yes, weight gain is a documented side effect of this medicine. This effect is often due to the drug’s primary action of promoting salt and water retention (edema) in the body. Official guidance emphasizes the importance of monitoring for sudden weight changes while using the medication.

Q: How soon after starting treatment might a patient expect to notice the effects of Кортинефф?

The active substance is absorbed quickly after administration, but its clinical effect on the body’s salt and fluid balance takes longer to develop. Official studies indicate the full onset of therapeutic action may require one to two days after starting treatment.

Q: What happens in the body if a dose of Кортинефф is missed?

If a dose is missed, official patient instructions advise taking it as soon as possible, unless it is almost time for the next scheduled dose. If that is the case, the missed dose should be skipped entirely. Regulatory instructions state that doses should not be doubled to compensate.

Q: Are there any over-the-counter medications or supplements that should be avoided while taking Кортинефф?

Official labeling notes a potential interaction with the substance Licorice. There is also an advisory for caution with certain medications like Aspirin in specific patient groups. Furthermore, regulatory sources advise careful monitoring when using any product that may affect potassium levels.

Q: Is the active ingredient in Кортинефф available in a generic formulation?

Yes, the active ingredient, Fludrocortisone acetate, is available in generic formulations approved by regulatory bodies like the FDA. These generic versions contain the same active ingredient and are considered therapeutically equivalent to the brand-name medicine.

Q: What is the difference between the labeled indications and other common uses of Кортинефф?

The officially labeled indications are specific hormone deficiency states like Primary Adrenocortical Insufficiency and Salt-Losing Adrenogenital Syndrome. While the medication is studied and sometimes used for other purposes, such as certain types of Orthostatic Hypotension, these are considered non-labeled or supportive uses.

Q: What should be done if a patient experiences unusual swelling while on Кортинефф?

Unusual swelling (edema) in the face, lower legs, or ankles is a sign of fluid imbalance. Regulatory guidelines emphasize that swelling should be reported to a healthcare provider promptly. Official information indicates that the dosage often requires reduction if signs of edema or transient hypertension develop.

Q: Can Кортинефф affect a person's sleep patterns or energy levels?

Official reporting notes that difficulty sleeping, or insomnia, is a possible adverse reaction. Furthermore, experiencing unusual fatigue or tiredness may be an indication of an electrolyte imbalance, such as low potassium, which is a known effect of this drug.

Q: What are the signs of too much or too little mineralocorticoid activity from Кортинефф?

Signs of too much activity can include symptoms like high blood pressure, swelling (edema), and very low potassium levels. Conversely, symptoms of too little activity can include unusual weakness, dizziness, or vomiting, particularly during periods of stress or illness.

Q: How does the clearance of Кортинефф from the body typically work?

Official pharmacokinetic data states that the medicine is primarily processed, or metabolized, in the liver. It is then eliminated from the body largely through the urine. The biological effect of the drug is noted to last for approximately 18 to 36 hours.

Q: What is the typical timeframe for side effects to appear after starting Кортинефф?

The timeframe varies, but official information indicates that some mild side effects may lessen within the first few days as the body adjusts to the medication. However, serious adverse effects, such as cataracts or bone loss, are generally only associated with prolonged or long-term use.

Q: Can patients with pre-existing mental health conditions safely use Кортинефф?

The official prescribing information advises caution, stating that corticosteroids can potentially aggravate pre-existing emotional instability or psychotic tendencies. Official documentation advises that a healthcare provider should be made aware of any history of mental health conditions.

Q: Is it possible to develop a dependence on Кортинефф?

The body can develop a physical reliance on the medicine because it suppresses the body's natural hormone production. Regulatory information emphasizes that abrupt discontinuation is strictly advised against, as it can cause a condition called secondary adrenocortical insufficiency. Dosage is required to be gradually reduced under the direction of a healthcare provider.

How should Кортинефф be stored and disposed of?

Official Storage and Disposal Guidelines for Cortineff (Fludrocortisone Acetate)

The official regulatory documents establish mandatory requirements for storing and disposing of Cortineff to maintain its stability and ensure safety.

Storage Conditions

Storage Factor Official Requirement
Temperature Store either refrigerated (2 C to 8 C) or at Controlled Room Temperature (20 C to 25 C), based on the specific product labeling.
Container Keep the medication in the original, tightly closed, light-resistant container.
Protection Must be protected from excessive heat and moisture.

Disposal and Handling

Expired or unused Cortineff must be disposed of according to local pharmaceutical waste regulations and should not be placed in household trash or flushed down the toilet, due to environmental concerns. Always keep this medication out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Кортинефф found in:

A-Z Index: